MPA made a submission to the PBAC for the consideration of the reimbursement of Nivolumab (Opdivo) and ipilumimab (Yervoy) and we thank all those that contributed their stories. Real stories provide real insights and these are invaluable! The PBAC will meet in March to consider this treatment option for reimbursement and we will advise you of the outcomes once we have any news. MPA maintains that all patients deserve access to the best evidence based treatments available.
Melanoma Patients Australia recognises Aboriginal and Torres Strait Islander Peoples as the Traditional Owners and Custodians of Australia, and we acknowledge, respect and embrace their continued connection to land, waters and community. We pay our respect to all Aboriginal and Torres Strait Islander Elders past, present and emerging.
We recognise, value and celebrate diversity and act in the spirit of inclusion.